Description
The authors acknowledge that understanding of ALS causation is incomplete despite identifying over 27 genes. This knowledge gap limits development of comprehensive diagnostic approaches and personalized therapies for all ALS patients.
Gap type: open_question Source paper: Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. (2018, The Lancet. Neurology, PMID:29154141)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:39.414885+00:00”, “resolution_summary”: “Resolved by hypothesis h-f373e16bb108: EZH2-Mediated H3K27me3 Spreading in Senescent ALS Microglia Silences Neuroprotective Gene Programs — Reversible by EZH2 Inhibitors. Supporting evidence includes debate sess_SDA-2026-04-13-gap-pubmed-20260410-165527-8256a071_20260414-013429.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-f373e16bb108”, “title”: “EZH2-Mediated H3K27me3 Spreading in Senescent ALS Microglia Silences Neuroprotective Gene Programs — Reversible by EZH2 Inhibitors”, “score”: 0.221, “reason”: “9 token overlaps; entity overlap: als”, “analysis_id”: “SDA-2026-04-26-gap-20260425215446”, “target_gene”: “EZH2 (PRC2) → H3K27me3 silencing of BDNF, GRN, TREM2, MerTK”, “target_pathway”: null, “disease”: “ALS”, “composite_score”: 0.7136330000000001, “confidence_score”: 0.28, “status”: “proposed”, “pubmed_evidence_ids”: [“31048495”, “31202798”, “32553389”, “32933418”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-165527-8256a071_20260414-013429”, “title”: “The authors explicitly state that the effects of these novel genes (MATR3, CHCHD10, TBK1, TUBA4A, NEK1, C21orf2, and CCNF) have not yet been investigated in animal models. This is critical for understanding pathogenic mechanisms and translating findings to clinical practice.\n\nGap type: open_question\nSource paper: Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. (2018, The Lancet. Neurology, PMID:29154141)”, “score”: 0.594, “reason”: “18 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-165527-8256a071”, “quality_score”: 0.71, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd_task_9aae8fc5”, “title”: “While ALS-causing mutations impair autophagy factors, the neuron-specific effects remain incompletely defined according to the authors. This knowledge gap prevents precise understanding of selective neuronal vulnerability in ALS.\n\nGap type: open_question\nSource paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)”, “score”: 0.558, “reason”: “11 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd”, “quality_score”: 0.812, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c_task_9aae8fc5”, “title”: “The abstract identifies that neurons show resistance to autophagy induction, but the mechanistic basis remains incompletely defined. Understanding this resistance is crucial for developing neuron-targeted autophagy therapies for ALS.\n\nGap type: unexplained_observation\nSource paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)”, “score”: 0.539, “reason”: “10 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-183548-043c7918”, “title”: “The authors evaluate several ALS-associated mutations in OPTN’s leucine-zipper domain but don’t fully explain how these mutations mechanistically lead to disease pathogenesis. Understanding this link is critical for developing targeted ALS therapies.\n\nGap type: unexplained_observation\nSource paper: Molecular Basis of the Recognition of the Active Rab8a by Optineurin. (2024, Journal of molecular biology, PMID:39374890)”, “score”: 0.484, “reason”: “9 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-183548-043c7918”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88_20260413-225852”, “title”: “The study shows VCP-mutant astrocytes exhibit hypoxia response activation without actual hypoxia, but the mechanistic link between VCP dysfunction and HIF-1α stabilization remains unexplained. Understanding this connection is critical for developing targeted therapies that could prevent early pathogenic events in VCP-ALS.\n\nGap type: unexplained_observation\nSource paper: Hypoxic stress is an early pathogenic event in human VCP-mutant ALS astrocytes. (2026, Stem cell reports, PMID:41349534)”, “score”: 0.468, “reason”: “9 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88”, “quality_score”: 0.78, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}